Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Stock Rated “Moderate Buy” by Wall Street Brokerages

Posted by Brian Himes on Oct 9th, 2026

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Free Report) have received an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $3.17.

Several equities analysts have commented on the stock. Piper Sandler reiterated an “overweight” rating and issued a $4.00 price target on shares of Inovio Pharmaceuticals in a research note on Monday, August 3rd. Wall Street Zen raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Weiss Ratings downgraded Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 13th. HC Wainwright reaffirmed a “neutral” rating on shares of Inovio Pharmaceuticals in a research report on Thursday, August 13th. Finally, Zacks Research raised shares of Inovio Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, August 12th.

Read Our Latest Analysis on Inovio Pharmaceuticals

Institutional Trading of Inovio Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in INO. Eversept Partners LP acquired a new position in shares of Inovio Pharmaceuticals during the first quarter worth about $1,802,000. Renaissance Technologies LLC lifted its position in Inovio Pharmaceuticals by 16.4% in the first quarter. Renaissance Technologies LLC now owns 643,777 shares of the biopharmaceutical company’s stock valued at $1,120,000 after purchasing an additional 90,613 shares during the period. Green Alpha Advisors LLC lifted its position in Inovio Pharmaceuticals by 68.8% in the third quarter. Green Alpha Advisors LLC now owns 114,857 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 46,802 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Inovio Pharmaceuticals by 1,929.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 48,948 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 46,536 shares during the period. Finally, Engineers Gate Manager LP purchased a new stake in shares of Inovio Pharmaceuticals in the second quarter valued at approximately $37,000. 26.79% of the stock is owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Trading Down 5.6%

Inovio Pharmaceuticals stock opened at $1.09 on Friday. The stock has a market cap of $112.71 million, a P/E ratio of -1.20 and a beta of 1.61. The company has a fifty day simple moving average of $1.13 and a 200-day simple moving average of $1.18. Inovio Pharmaceuticals has a 12-month low of $0.56 and a 12-month high of $2.72.

Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) last posted its earnings results on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15. As a group, sell-side analysts forecast that Inovio Pharmaceuticals will post -0.72 earnings per share for the current fiscal year.

About Inovio Pharmaceuticals

(Get Free Report)

Inovio Pharmaceuticals, Inc (NASDAQ: INO) is a biotechnology company focused on developing DNA medicines, including immunotherapies and vaccines designed to stimulate targeted immune responses. Its technology platform uses synthetic DNA constructs delivered into cells, with the company’s CELLECTRA device platform developed to enhance cellular uptake.

Inovio’s pipeline has included candidates for infectious diseases, cancers and other conditions involving the immune system. Its lead programs have included INO-3107, an investigational DNA immunotherapy being developed for recurrent respiratory papillomatosis, and VGX-3100, an earlier candidate studied for human papillomavirus-related disease.